![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novartis and NHS England Agree on Kymriah Deal
Novartis and NHS England Agree on Kymriah Deal
September 10, 2018
NHS England and Novartis, manufacturer of the CAR-T therapy Kymriah, agreed on a deal that will make the drug available to the national health service’s cancer patients.
The deal came less than 10 days after the B-cell ALL treatment was approved for European marketing. The drug is part of a long-term plan by NHS to improve its cancer services.
“CAR-T therapy is a true game changer, and NHS cancer patients are now going to be amongst the first in the world to benefit,” said Simon Stevens, NHS England’s chief executive.
Upcoming Events
-
21Oct